(168 days)
Nihon Kohden's model number OGS-2001A is intended for medical use to measure the blood oxygen saturation (SpO2) and to measure the concentration of carbon dioxide in a gas mixture to aid in determining the patient's ventilatory status (CO2).
This product will be available for use by medical personnel within a medical facility or in a remote environment including transport. This device is not intended to be the sole basis of diagnosis.
The CO2 function of the device is intended for patients three (3) years and above and is not recommended for patients with low tidal volume such as patients weighing less than 22 pounds or patients with a respiratory rate greater than 60 breaths per minute. The CO2 function will be available for all other patient populations.
The OGS-2001A device is not sterile. The airway adapter is for single patient use only. Reusable or single patient use SpO2 probes are available.
The device material components have been determined to be non-contacting per the quidance provided by BS EN 30993: 1994 / ISO 10993: 1993 which replaces the Tripartite Guidance. The reusable SpO2 probe surface is silicone, known to be biocompatible by over 30 years of various medical device uses per the open literature. The disposable, SpO2 probes are the same probes as used with the predicate device BSM-1101 (K973918). Therefore, good laboratory practice studies were not required per 21 CFR 58.
The OGS-2001A PocketCare was subjected to electromagnetic, environmental, safety and performance testing procedures per Nihon Kohden design control requirements. These tests verified the operation of the device. Software validation tested the operation of the software functions of acquiring. processing, displaying and recording all functions of the results confirmed that the device performed within specifications.
Here's an analysis of the provided text regarding the OGS-2001A PocketCare device, addressing your specific questions:
This document is a 510(k) submission for the Nihon Kohden OGS-2001A PocketCare, a medical device intended to measure blood oxygen saturation (SpO2) and carbon dioxide concentration (CO2).
1. Table of acceptance criteria and the reported device performance
The provided text does not explicitly state specific numerical acceptance criteria for performance metrics (e.g., accuracy, precision) for either SpO2 or CO2 measurements. It states that:
- "Software validation tested the operation of the software functions of acquiring, processing, displaying and recording all functions of the results confirmed that the device performed within specifications."
This indicates that the device met its internal specifications, but these specifications themselves are not detailed in the provided documents.
| Acceptance Criteria (Not Explicitly Stated) | Reported Device Performance |
|---|---|
| (Assumed: Device operates as intended and meets internal specifications for SpO2 and CO2 measurement accuracy and functionality) | "Software validation tested the operation of the software functions of acquiring, processing, displaying and recording all functions of the results confirmed that the device performed within specifications." "The OGS-2001A PocketCare was subjected to electromagnetic, environmental, safety and performance testing procedures per Nihon Kohden design control requirements. These tests verified the operation of the device." |
2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)
The document does not provide details on the sample size for a test set, nor does it specify the data provenance (e.g., country of origin, retrospective/prospective nature). The focus is on verifying compliance with design controls, software validation, and substantial equivalence to predicate devices, rather than a clinical performance study with human subjects for independent validation of accuracy.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not describe any process involving experts to establish a "ground truth" in the context of a clinical test set. The validation described is related to engineering and software performance against internal specifications.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
Since no clinical test set with expert ground truth establishment is described, there is no adjudication method mentioned.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This document is for a basic SpO2/CO2 monitoring device. It does not describe a multi-reader multi-case (MRMC) comparative effectiveness study, nor does it involve AI assistance in the way typically understood for such studies.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
The document describes "software validation tested the operation of the software functions of acquiring, processing, displaying and recording all functions of the results." This statement suggests that the standalone performance of the device's algorithms and software was indeed tested against its specifications. However, the specifics of these tests (e.g., using simulated data, phantom measurements, or patient data) are not detailed.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
The document does not explicitly state the type of "ground truth" used for performance validation. Given the nature of SpO2 and CO2 measurements, it's highly probable that:
- For SpO2: co-oximetry (blood gas analysis) would be the gold standard "ground truth" in any clinical accuracy study, but such a study is not detailed here.
- For CO2: validated gas mixtures or a reference gas analyzer would be used as "ground truth" for calibration and accuracy testing.
The document refers to "specifications," implying that performance was compared against these predefined standards, which would have been established based on accepted physiological principles and potentially reference methods, but this is not explicitly called out as "ground truth" in the provided text.
8. The sample size for the training set
The document does not mention a "training set" as this device does not appear to utilize machine learning or AI models that require data training in the modern sense. Its validation is based on traditional engineering and software verification methods.
9. How the ground truth for the training set was established
As there is no training set mentioned, the method for establishing its ground truth is also not applicable.
{0}------------------------------------------------
NIHON KOHDEN AMERICA, INC. July 22, 1999
510(k) NOTIFICATION
OGS-2001A PocketCare
JAN - 7 2000
SECTION 2 - 510(K) SUMMARY
Name and Address of Applicant Nihon Kohden America. Inc. Attn: Regulatory Affairs 2601 Campus Drive Irvine, California 92612-1601
Phone: (949) 250-3959 Fax: (949) 250-3210
The device has been classified as Class II by the Cardiovascular Device Classification Panel under 21 CFR Part 870.2700 "Oximeter" per 74 DQA and by the Anesthesiology Classification Panel under 21 CFR Part 868.1400 Analyzer, Gas, Carbon dioxide, Gaseous-phase" per 73 CCK.
The common name for the OGS-2001A device is SpO2/CO2 monitor.
The predicate devices are the OLG-1100A PocketCap CO2 Monitor per 510(K) #K964305 commercial distribution certification dated 02/19/1997and the BSM-1101 Life Scope EC Patient Monitor per 510(k) #K973918, commercial distribution certification dated 01/13/1998.
Nihon Kohden's model number OGS-2001A is intended for medical use to measure the blood oxygen saturation (SpO-) and to measure the concentration of carbon dioxide in a gas mixture (CO-) to aid in determining the patient's ventilatory status. This product will be available for use by medical personnel within a medical facility or in a remote environment. This device is not intended to be the sole basis of diagnosis.
The CO2 function of the device is intended for patients three (3) years and above and is not recommended for patients with low tidal volume such as patients weighing less than 22 pounds or patients with a respiratory rate greater than 60 breaths per minute. The CO2 function will be available for all other patient populations.
The device complies with IEC 601-1 subclause 56.3(c) implemented by 21 CFR Part 868 Performance Standard for Electrode Lead Wires and Patient Cables. To date, no other special controls or performance standards are known or established for this device.
The OGS-2001A device is not sterile. The airway adapter is for single patient use only. Reusable or single patient use SpO2 probes are available.
The device material components have been determined to be non-contacting per the quidance provided by BS EN 30993: 1994 / ISO 10993: 1993 which replaces the Tripartite Guidance. The reusable SpO2 probe surface is silicone, known to be biocompatible by over 30 years of various medical device uses per the open literature. The disposable, SpO2 probes are the same probes as used with the predicate device BSM-1101 (K973918). Therefore, good laboratory practice studies were not required per 21 CFR 58.
The OGS-2001A PocketCare was subjected to electromagnetic, environmental, safety and performance testing procedures per Nihon Kohden design control requirements. These tests verified the operation of the device. Software validation tested the operation of the software functions of acquiring. processing, displaying and recording all functions of the results confirmed that the device performed within specifications.
Therefore based on the above, Nihon Kohden believes that the OGS-2001A PocketCare is substantially equivalent to the combination of the predicate devices.
{1}------------------------------------------------
SECTION 3 - PROPOSED LABELING
A. Intended Use
The OGS-2001A PocketCare is intended for medical purposes to transmit radiation at a known wavelength through blood and measure the blood oxygen saturation based on the amount of reflected or scattered radiation and is intended to measure the concentration of carbon dioxide in a gas mixture to aid in determining the patient's ventilatory status.
B. Device/Package Labels
Drawings of the device and the proposed product labels are provided in attachment 1.
C. Proposed Packaging
Packaging for the OGS-2001A PocketCare is depicted in Attachment 2.
D. Instructions for Use
The proposed instructions for use are provided with each packaged device and are presented in Attachment 8.
ய் Advertisement/Promotional Literature
To date no advertisement or promotional literature has been created for the OGS-2001A PocketCare device for distribution in the United States.
F. Contraindications, Precautions & Warnings
Warnings and cautions are listed in the Operator's Manual as shown in Attachment 3.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles three overlapping human profiles or faces, with flowing lines that suggest movement or progress.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN - 7 2000
Mr. Bonnie Bishop Nihon Kohden America, Inc. 2601 Campus Drive Irvine, CA 92612
Re: K992455 Nihon Kohden OGS-2001A PocketCare Regulatory Class: II (two) 74 DQA Product Code: Dated: November 5, 1999 November 8, 1999 Received:
Dear Mr. Bishop:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual reqistration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{3}------------------------------------------------
Page 2 - Mr. Bonnie Bishop
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
jocconi H. Westendorp fes,
Celia M. Witten, Ph.D., M.D. Acting Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
NIHON KOHDEN AMERICA, INC. July 22, 1999
G. Indications for Use Statement
510(k) Number (if known): __
Device Name: OGS-2001A PocketCare
Indications for Use:
Nihon Kohden's model number OGS-2001A is intended for medical use to measure the blood oxygen saturation (SpO2) and to measure the concentration of carbon dioxide in a gas mixture to aid in determining the patient's ventilatory status (CO2).
This product will be available for use by medical personnel within a medical facility or in a remote environment including transport. This device is not intended to be the sole basis of diagnosis.
The CO2 function of the device is intended for patients three (3) years and above and is not recommended for patients with low tidal volume such as patients weighing less than 22 pounds or patients with a respiratory rate greater than 60 breaths per minute. The CO2 function will be available for all other patient populations.
Joan Awher
PRESCRIPTION
Image /page/4/Picture/12 description: The image shows a hand-drawn symbol that resembles a stylized 'X' above a horizontal line. The 'X' is formed by two diagonal lines that intersect in the middle. The horizontal line is positioned directly below the 'X', creating a base or foundation for the symbol. The drawing appears to be simple and lacks any shading or color.
ાર્વદ
OVER - THE - COUNTER USE -
§ 870.2700 Oximeter.
(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).